FiercePharma9h
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
pharmaphorum5d
Merck axes hepatitis C drug development
Merck & Co has axed two hepatitis drugs in its pipeline, a further indication that competitors think the market has peaked. The company already markets Zepatier (elbasvir+grazoprevir), which got ...
FiercePharma13d
Gardasil's China troubles haunt Merck in Q3, with execs warning of more obstacles ahead
While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...
pharmaphorum8d
FDA stifles Merck's cough drug gefapixant, asking for more data
Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its ...